Hypokalemia in thiazide-treated systemic hypertension.
Potassium supplementation in diuretic-induced hypokalemia (serum potassium less than 3.5 mmol/liter) in patients being treated for hypertension is a common event. In a previous study 40 mmol/day of orally administered potassium was not effective in preventing diuretic-induced hypokalemia in patients who had previously developed hypokalemia while being treated for hypertension with hydrochlorothiazide. In the study reported here dosages as high as 60 to 80 mmol/day of orally administered potassium failed to prevent hypokalemia in 7 of 19 hypertensive patients who were receiving hydrochlorothiazide. Potassium supplementation was compared with the potassium-sparing diuretic amiloride. The study design was open label and subject matched with crossover of therapeutic regimens.
D000450:Aldosterone / Q000097:blood; D000584:Amiloride / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D007008:Hypokalemia / Q000139:chemically induced*; D008274:Magnesium / Q000097:blood; D011188:Potassium / Q000097:blood; D011189:Potassium Chloride / Q000008:administration & dosage / Q000627:therapeutic use; D011897:Random Allocation; D012083:Renin / Q000097:blood
D006852:Hydrochlorothiazide; D000450:Aldosterone; D011189:Potassium Chloride; D000584:Amiloride; D012083:Renin; D008274:Magnesium; D011188:Potassium